Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
The Journal of Headache and Pain
Published in: The Journal of Headache and Pain 1/2021

01-12-2021 | Migraine | Research article

Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study

Authors: Sara Bottiroli, Roberto De Icco, Gloria Vaghi, Stefania Pazzi, Elena Guaschino, Marta Allena, Natascia Ghiotto, Daniele Martinelli, Cristina Tassorelli, Grazia Sances

Published in: The Journal of Headache and Pain | Issue 1/2021

Login to get access

Abstract

Background

Monoclonal antibodies (mABs) targeting the calcitonin gene-related peptide (CGRP) pathway represent the first disease-specific preventive migraine therapy. Growing evidence suggests that they are effective in the preventive treatment of difficult-to-treat patients. In this study, we evaluated the psychological predictors of the outcome of treatment with the anti-CGRP monoclonal antibody erenumab in patients with chronic migraine (CM).

Methods

Seventy-five patients with CM who had already failed at least 3 preventive therapies received erenumab every 28 days for a period of 12 months. Before the first administration, patients received a full psychological evaluation using The Structured Clinical Interview for DSM-5 Clinician Version (SCID-5-CV) to assess personality disturbances (primary outcome), mood and anxiety disorders, and as well specific questionnaires to evaluate alexithymia traits, childhood traumas, and current stressors (secondary outcomes).

Results

After 12 months of treatment, 53 patients reported a reduction of at least 50% in headache days/per month (Responders), whereas 22 did not (Non Responders). When compared to Responders, Non Responders were characterized by a higher prevalence of personality disorders belonging to Cluster C (avoidant, dependent, and obsessive-compulsive) (77% vs 37%, p = .001). Non Responders were also characterized by a higher prevalence of anxiety disorders (90% vs 60%, p = 0.007), showed more alexithymic traits (51.7 ± 13.7 vs 42.9 ± 14.3, p = 0.017), and reported a higher number of 'at least serious' current stressors (3.2 ± 4.0 vs 0.8 ± 1.4, p < .0001) than Responders. At the multivariate analysis, higher prevalence of Cluster C personality disorders (OR 3.697; p = 0.05) and higher number of ‘at least serious’ life events (OR 1.382; p = 0.017) arose as prognostic factors of erenumab failure.

Conclusions

Erenumab confirmed its effectiveness in a population of difficult-to-treat migraine. The presence of “anxious-fearful” personality together with current stressors and anxiety represent negative predictors of treatment outcome.

Trial registration

The study protocol was registered at clinicaltrials.gov (NCT04361721).
Literature
1.
Viana M, Bottiroli S, Sances G et al (2018) Factors associated to chronic migraine with medication overuse: a cross-sectional study. Cephalalgia 38:2045–2057PubMedCrossRef
2.
Bottiroli S, Galli F, Viana M et al (2019) Negative short-term outcome of detoxification therapy in chronic migraine with medication overuse headache: role for early life traumatic experiences and recent stressful events. Front Neurol 10:173PubMedPubMedCentralCrossRef
3.
Sances G, Ghiotto N, Galli F et al (2010) Risk factors in medication-overuse headache: a 1-year follow-up study (care II protocol). Cephalalgia 30:329–336PubMedCrossRef
4.
Sances G, Galli F, Ghiotto N et al (2013) Factors associated with a negative outcome of medication-overuse headache: a 3-year follow-up (the ‘CARE’ protocol). Cephalalgia 33:431–443PubMedCrossRef
5.
Bottiroli S, Viana M, Sances G et al (2016) Psychological factors associated with failure of detoxification treatment in chronic headache associated with medication overuse. Cephalalgia 36:1356–1365PubMedCrossRef
6.
Galli F, Tanzilli A, Simonelli A et al (2019) Personality and personality disorders in medication-overuse headache: a controlled study by SWAP-200. Pain Res Manag 2019:1874078PubMedPubMedCentralCrossRef
7.
Galli F, Caputi M, Sances G et al (2017) Alexithymia in chronic and episodic migraine: a comparative study. J Ment Health 26:192–196PubMedCrossRef
8.
Bottiroli S, Galli F, Viana M et al (2018) Traumatic experiences, stressful events, and alexithymia in chronic migraine with medication overuse. Front Psychol 9:704PubMedPubMedCentralCrossRef
9.
Seng EK, Seng CD (2016) Understanding migraine and psychiatric comorbidity. Curr Opin Neurol 29:309–313PubMedCrossRef
10.
11.
Charles A, Pozo-Rosich P (2019) Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet 394(10210):1765–1774PubMedCrossRef
12.
13.
Ashina M, Tepper S, Brandes JL et al (2018) Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia 38(10):1611–1621PubMedCrossRef
14.
15.
16.
Dresler T, Caratozzolo S, Guldolf K et al (2019) Understanding the nature of psychiatric comorbidity in migraine: a systematic review focused on interactions and treatment implications. J Headache Pain 20(1):51PubMedPubMedCentralCrossRef
17.
Mastria G, Viganò A, Corrado A et al (2021) Chronic migraine preventive treatment by prefrontal-occipital Transcranial direct current stimulation (tDCS): a proof-of-concept study on the effect of psychiatric comorbidities. Front Neurol 12:654900PubMedPubMedCentralCrossRef
18.
Bottiroli S, Allena M, Sances G et al (2019) COMOESTAS consortium. Psychological, clinical, and therapeutic predictors of the outcome of detoxification in a large clinical population of medication-overuse headache: a six-month follow-up of the COMOESTAS project. Cephalalgia 39(1):135–147PubMedCrossRef
19.
Bottiroli S, Allena M, Sances G et al (2018) Changes in anxiety and depression symptoms associated to the outcome of MOH: a post-hoc analysis of the Comoestas project. Cephalalgia 38(4):646–654PubMedCrossRef
20.
Tietjen GE, Brandes JL, Peterlin BL et al (2010) Childhood maltreatment and migraine (part II). Emotional abuse as a risk factor for headache chronification. Headache 50(1):32–41PubMedCrossRef
21.
Schramm SH, Moebus S, Lehmann N et al (2015) The association between stress and headache: a longitudinal population-based study. Cephalalgia 35(10):853–863PubMedCrossRef
22.
Andrasik F, Flor H, Turk DC (2005) An expanded view of psychological aspects in head pain: the biopsychosocial model. Neurol Sci 26(Suppl 2):s87–s91PubMedCrossRef
23.
Headache Classification Committee of the International Headache Society (IHS) (2018) The international classification of headache disorders, 3rd edition. Cephalalgia 38:1–211
24.
De Icco R, Fiamingo G, Greco R et al (2020) Neurophysiological and biomolecular effects of erenumab in chronic migraine: an open label study. Cephalalgia 40(12):1336–1345PubMedCrossRef
25.
American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn. American Psychiatric Association, ArlingtonCrossRef
26.
First MB, Williams JB, Karg RS, Spitzer RL (2015) Structured clinical interview for DSM-5 disorders, clinician version (SCID-5-CV). American Psychiatric Association, Arlington
27.
Iani L, Lauriola M, Costantini MA (2014) Confirmatory bifactor analysis of the hospital anxiety and depression scale in an Italian community sample. Health Qual Life Outcomes 12:84PubMedPubMedCentralCrossRef
28.
Caretti V, Daniele V, La Barbera D (2005) Alessitimia, Valutazione e trattamento. Casa Editrice Astrolabio, Roma
29.
Kayhan F, Ilik F (2016) Prevalence of personality disorders in patients with chronic migraine. Compr Psychiatry 68:60–64PubMedCrossRef
30.
Cervone D, Pervin LA (2010) Personality: theory and research, 11th edn. Hoboken, NJ: Wiley
31.
Yang F, Dos Santos IAM, Gomez RS et al (2019) Personality disorders are associated with more severe forms of migraine. Acta Neurol Belg 119(2):201–205PubMedCrossRef
32.
Luconi R, Bartolini M, Taffi R et al (2007) Prognostic significance of personality profiles in patients with chronic migraine. Headache 47(8):1118–1124PubMedCrossRef
33.
Lake AE, Rains JC, Penzien DB et al (2005) Headache and psychiatric comorbidity: historical context, clinical implications, and research relevance. Headache 45(5):493–506PubMedCrossRef
34.
Angstman KB, Rasmussen NH (2011) Personality disorders: review and clinical application in daily practice. Am Fam Physician 84:1253–1260PubMed
35.
Wang W, Yang T, Zhu H et al (2005) Disordered personality traits in primary headaches. Soc Behav Pers 33:495–502CrossRef
36.
Wheaton MG, Ward HE (2020) Intolerance of uncertainty and obsessive-compulsive personality disorder. Personal Disord 11(5):357–364PubMedCrossRef
37.
Buhr K, Dugas MJ (2009) The role of fear of anxiety and intolerance of uncertainty in worry: an experimental manipulation. Behav Res Ther 47(3):215–223PubMedCrossRef
38.
Westen D, Shedler J (1999) Revising and assessing axis II, part I: developing a clinically and empirically valid assessment method. Am J Psychiatry 156(2):258–272PubMed
39.
Westen D, Shedler J (1999) Revising and assessing axis II, part II: toward an empirically based and clinically useful classification of personality disorders. Am J Psychiatry 156(2):273–285PubMed
40.
Radat F, Swendsen J (2005) Psychiatric comorbidity in migraine: a review. Cephalalgia 25(3):165–178PubMedCrossRef
41.
Trejo-Gabriel-Galan JM, Aicua-Rapún I, Cubo-Delgado E et al (2018) Suicide in primary headaches in 48 countries: a physician-survey based study. Cephalalgia 38(4):798–803PubMedCrossRef
42.
Horesh N, Amir M, Kedem P et al (1997) Life events in childhood, adolescence and adulthood and the relationship to panic disorder. Acta Psychiatr Scand 96(5):373–378PubMedCrossRef
43.
Newman SC, Bland RC (1994) Life events and the 1-year prevalence of major depressive episode, generalized anxiety disorder, and panic disorder in a community sample. Compr Psychiatry 35(1):76–82PubMedCrossRef
44.
Nash JM, Thebarge RW (2006) Understanding psychological stress, its biological processes, and impact on primary headache. Headache 46(9):1377–1386PubMedCrossRef
45.
Mosley TH, Penzien DB, Johnson CA et al (1991) Time-series analysis of stress and headache. Cephalalgia 11(11_suppl):306–307CrossRef
46.
Liu TH, Wang Z, Xie F et al (2021) Contributions of aversive environmental stress to migraine chronification: research update of migraine pathophysiology. World J Clin Cases 9(9):2136–2145PubMedPubMedCentralCrossRef
47.
Gündel H, Ceballos-Baumann AO, Von Rad M (2002) Aktuelles zu psychodynamischen und neurobiologischen Einflussfaktoren in der Genese der Alexithymie. Psychother Psychosom Med Psychol 52(11):479–486PubMedCrossRef
48.
Näätänen P, Ryynänen A, Keltikangas-Järvinen L (1999) The influence of Alexithymic characteristics on the self-perception and facial expression of a physiological stress state. Psychother Psychosom 68(5):252–262PubMedCrossRef
49.
Stone LA, Nielson KA (2001) Intact physiological response to arousal with impaired emotional recognition in alexithymia. Psychother Psychosom 70(2):92–102PubMedCrossRef
50.
Breslau N, Schultz L, Lipton R et al (2012) Migraine headaches and suicide attempt. Headache 52(5):723–731PubMedCrossRef
51.
52.
Grilo CM, McGlashan TH, Skodol AE (1998) Course and stability of personality disorders. J Psychiatr Pract 4:61–75CrossRef
53.
Grilo CM, Sanislow CA, Gunderson JG et al (2004) Two-year stability and change of schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders. J Consult Clin Psychol 72(5):767–775PubMedPubMedCentralCrossRef
54.
Ornello R, Casalena A, Frattale I et al (2020) Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region. J Headache Pain 21(1):102PubMedPubMedCentralCrossRef
55.
Silvestro M, Tessitore A, Scotto di Clemente F et al (2021) Refractory migraine profile in CGRP-monoclonal antibodies scenario. Acta Neurol Scand 144:325–333PubMedPubMedCentralCrossRef
56.
Barbanti P, Fofi L, Grazzi L et al (2021) IRON study group. Clinical features, disease progression, and use of healthcare resources in a large sample of 866 patients from 24 headache centers: a real-life perspective from the Italian chROnic migraiNe (IRON) project. Headache 61:936–950PubMedCrossRef
57.
Smitherman TA, Tietjen GE, Schuh K et al (2020) Efficacy of Galcanezumab for migraine prevention in patients with a medical history of anxiety and/or depression: a post hoc analysis of the phase 3, randomized, double-blind, placebo-controlled REGAIN, and pooled EVOLVE-1 and EVOLVE-2 studies. Headache 60:2202–2219PubMedPubMedCentralCrossRef
58.
Lipton RB, Cohen JM, Galic M et al (2021) Effects of fremanezumab in patients with chronic migraine and comorbid depression: subgroup analysis of the randomized HALO CM study. Headache 61(4):662–672PubMedPubMedCentralCrossRef
59.
Edvinsson L (2017) The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. Headache 57:47–55PubMedCrossRef
60.
Noseda R, Schain AJ, Melo-Carrillo A et al (2020) Fluorescently-labeled fremanezumab is distributed to sensory and autonomic ganglia and the dura but not to the brain of rats with uncompromised blood brain barrier. Cephalalgia 40:229–240PubMedCrossRef
61.
Ziegeler C, Mehnert J, Asmussen K, May A (2020) Central effects of erenumab in migraine patients: an event-related functional imaging study. Neurology 95(20):e2794–e2802PubMedCrossRef
62.
63.
Borsook D et al (2012) Understanding migraine through the lens of maladaptive stress responses: a model disease of allostatic load. Neuron 73:219–234PubMedCrossRef
64.
Buonvicino D, Urru M, Muzzi M, Ranieri G, Luceri C, Oteri C, Lapucci A, Chiarugi A (2018) Trigeminal ganglion transcriptome analysis in 2 rat models of medication-overuse headache reveals coherent and widespread induction of pronociceptive gene expression patterns. Pain 159:1980–1988PubMedCrossRef
65.
Iyengar S, Ossipov MH, Johnson KW (2017) The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine. Pain 158(4):543–559PubMedPubMedCentralCrossRef
66.
Sun H, Dodick DW, Silberstein S et al (2016) Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 15:382–390PubMedCrossRef
67.
Dodick DW, Goadsby PJ, Spierings EL et al (2014) Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol 13:885–892PubMedCrossRef
68.
Dodick DW, Goadsby PJ, Silberstein SD et al (2014) Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol 13:1100–1107PubMedCrossRef
69.
Bigal ME, Dodick DW, Rapoport AM et al (2015) Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 14:1081–1090PubMedCrossRef
Metadata
Title
Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study
Authors
Sara Bottiroli
Roberto De Icco
Gloria Vaghi
Stefania Pazzi
Elena Guaschino
Marta Allena
Natascia Ghiotto
Daniele Martinelli
Cristina Tassorelli
Grazia Sances
Publication date
01-12-2021
Publisher
Springer Milan
Published in
The Journal of Headache and Pain / Issue 1/2021
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI
https://doi.org/10.1186/s10194-021-01333-4

Other articles of this Issue 1/2021

The Journal of Headache and Pain 1/2021 Go to the issue

Research article

Long term safety, tolerability, and efficacy of intracutaneous zolmitriptan (M207) in the acute treatment of migraine

Review article

Comorbidities of primary headache disorders: a literature review with meta-analysis

Research article

Interleukin-6 induces spatially dependent whole-body hypersensitivity in rats: implications for extracephalic hypersensitivity in migraine

Research article

Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine

Research article

Disability, quality of life, productivity impairment and employer costs of migraine in the workplace

Research article

Post-reversible cerebral vasoconstriction syndrome headache